Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...

The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

Accessed via the internet, the online self-help programme is for people who binge eat, particularly those with bulimia nervosa, binge eating disorder, and similar eating problems. It's designed for ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its ...

This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...

There is a simple discount patient access scheme for efanesoctocog alfa. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

We have moved Health technology evaluation 20 to become HealthTech guidance 739. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...